Exact FDA event identifier

Event 98181

3 recalled-product records grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: December 18, 2025
Product types: Drug
Classifications: Class II
Statuses: Ongoing
Recalling firm wording: Imprimis NJOF, LLC

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

3 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 3

Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC, Ledgewood, NJ 07852, NDC 71384-512-0.1

D-0249-2026

Recall number: D-0249-2026
Initiated: December 18, 2025
Classification: Class II
Status: Ongoing
Recalling firm: Imprimis NJOF, LLC
Quantity: 778 boxes of 15,540 pre-filled syringes

App-derived interpretation

Foreign material or chemical contamination reason.foreign_material_chemical_contamination · v1.0.0

particulate matter

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Presence of particulate matter - Glass like particles.

Code information

Lot: 25MAY051, Expires: 06/26/2026; 25AUG003, Expires:08/07/2026

Distribution pattern

U.S Nationwide

drug · product 2 of 3

Dexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, NDC 71384-513-01.

D-0250-2026

Recall number: D-0250-2026
Initiated: December 18, 2025
Classification: Class II
Status: Ongoing
Recalling firm: Imprimis NJOF, LLC
Quantity: 596 boxes of 11,920 pre-filled syringes

App-derived interpretation

Foreign material or chemical contamination reason.foreign_material_chemical_contamination · v1.0.0

particulate matter

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Presence of particulate matter - Glass like particles.

Code information

Lot: 25APR001A, 25APR001B, Expires: 04/03/2026.

Distribution pattern

U.S Nationwide

drug · product 3 of 3

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

D-0251-2026

Recall number: D-0251-2026
Initiated: December 18, 2025
Classification: Class II
Status: Ongoing
Recalling firm: Imprimis NJOF, LLC
Quantity: 314 boxes of 6,280 pre-filled syringes

App-derived interpretation

Foreign material or chemical contamination reason.foreign_material_chemical_contamination · v1.0.0

particulate matter

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Presence of particulate matter - Glass like particles.

Code information

Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.

Distribution pattern

U.S Nationwide